Videos

Niraparib Plus Abiraterone Acetate and Prednisone for Metastatic Castration-Resistant Prostate Cancer With HRR Gene Alterations
Final Analysis of the Phase 3 MAGNITUDE Trial

11/01/2023

Elena Castro, MD, PhD, Hospital Universitario 12 de Octubre, Madrid, Spain, discusses the final analysis of the phase 3 MAGNITUDE trial. This study compared niraparib plus abiraterone acetate and prednisone (AAP) with placebo plus AAP among patients with metastatic castration-resistant prostate cancer (CRPC) and homologous recombination repair (HRR) gene alterations.

In this trial, Dr Castro stated, “we have seen an overall survival benefit from the combination [of abiraterone plus niraparib] for patients with BRCA1 and BRCA2 mutations." She added, "We should make the effort of identifying all our patients with BRCA mutations to offer them treatment with a PARP inhibitor as soon as possible."

These results were first presented by Kim Nguyen Chi, MD, BC Cancer and Vancouver Prostate Centre at University of British Columbia, Vancouver, British Columbia, Canada, at the 2023 European Society for Medical Oncology Annual Congress in Madrid, Spain.

Transcript:

Hi, my name is Elena Castro. I'm a medical oncologist at Hospital University 12 de Octubre in Madrid, Spain. At ESMO 2023, the final results of the overall survival of the MAGNITUDE study have been presented.

MAGNITUDE is a randomized phase 3 study that investigated the benefit of combining abiraterone and niraparib in first-line treatment of metastatic castration-resistant prostate cancer. Patients were screened for alterations in HRR genes. Those patients who presented at least 1 alteration in these genes were included in cohort 1, and patients without any alterations were included in cohort 2. Within each cohort, patients were randomized to receive abiraterone alone or in combination with niraparib. The primary objective of this study was radiographic progression-free survival.

A futility analysis of the study suggested no benefit from the combination in cohort 2, patients without HRR alterations, and that cohort was closed. For patients with alterations in HRR genes, the primary objective was met with a benefit in [radiographic progression-free survival] rPFS from the combination of niraparib and abiraterone. Those results have already been presented in prior meetings.

Now we have learned the final results of the overall survival analysis. In a meta-analysis that included different risk factor and accounted for some imbalances in the populations observed in the treatment and control arms, we have seen a benefit and overall survival benefit from the combination for patients with BRCA1 and BRCA2 mutations. This is very important because we know that these patients have very poor outcomes when conventionally treated with taxanes or hormonal agents that we use for the treatment of mCRCP patients.

I think from now on, we should make the effort of identifying all our patients with BRCA mutations to offer them treatment with a PARP inhibitor as soon as possible.

Source:

Chi KNN, Castro E, Attard G, et al. Niraparib (NIRA) with abiraterone acetate plus prednisone (AAP) as first-line (1L) therapy in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) and homologous recombination repair (HRR) gene alterations: Three-year update and final analysis (FA) of MAGNITUDE. Presented at 2023 ESMO Annual Congress; October 20-24, 2023; Madrid, Spain. LBA85

© 2023 HMP Global. All Rights Reserved.
Any views and opinions expressed are those of the author(s) and/or participants and do not necessarily reflect the views, policy, or position of Oncology Learning Network or HMP Global, their employees, and affiliates.

Recent News

News

Naporafenib in Combination With Rineterkib or Tremetinib for KRAS- or BRAF-Mutant Non-Small Cell Lung Cancer

11/07/2024

Allison Casey ;

While naporafenib plus rineterkib and naporafenib plus trametinib both had acceptable safety profiles, antitumor activity was limited among patients with KRAS-/BRAF-mutant non-small cell lung cancer.

While naporafenib plus...

11/07/2024

Oncology

News

Addition of Concurrent Thoracic Radiotherapy to First-Line TKI Therapy Improves Survival for Patients With EGFR-Mutated Non-Small Cell Lung Cancer

11/06/2024

Stephanie Holland ;

According to results from a phase 3 trial, the addition of concurrent thoracic radiotherapy to first-line icotinib improved survival among patients with EGFR-mutated oligo-organ metastatic non-small cell lung cancer.

According to results from a...

11/06/2024

Oncology

News

Ipilimumab After PD-1 Inhibition Failure Among Patients With Metastatic Melanoma

11/05/2024

Allison Casey ;

A single-center real-world study found the use of ipilimumab in the second-line was an effective therapy for patients with metastatic BRAF/NRAS-wildtype metastatic melanoma without brain metastases.

A single-center real-world study...

11/05/2024

Oncology

News

Extended Lymphadenectomy Fails to Improve Survival Outcomes for Patients With Muscle-Invasive Bladder Cancer

11/05/2024

Stephanie Holland ;

Results from the phase 2 SWOG S1011 study demonstrated that extended lymphadenectomy failed to improve survival compared to standard lymphadenectomy among patients with localized muscle-invasive bladder cancer.

Results from the phase 2 SWOG...

11/05/2024

Oncology

News

Tumor Molecular Features Contribute Substantially to Overall Survival Disparities Among Patients With Colorectal Cancer

11/05/2024

Allison Casey ;

According to a single-center cohort study, there was a substantial overall survival disparity, with differing frequencies of driver gene variations, by race and ethnicity.

According to a single-center...

11/05/2024

Oncology

News

First-Line Durvalumab Plus Platinum-Doublet Chemotherapy Prolongs Survival for Patients With Extensive-Stage Small Cell Lung Cancer

11/04/2024

Stephanie Holland ;

According to results from a real-world comparison study, first-line durvalumab plus platinum-doublet chemotherapy prolonged survival compared to first-line atezolizumab plus platinum-doublet chemotherapy for patients with extensive-stage...

According to results from a...

11/04/2024

Oncology

News

Gilteritinib Following AlloHCT Shows No Improvement in Health-Related Quality of Life Among Patients With FLT3-ITD AML

10/31/2024

Gilteritinib maintenance therapy following allogeneic hematopoietic cell transplantation among patients with FLT3-ITD acute myeloid leukemia was not associated with any difference in health-related quality of life when compared with a...

Gilteritinib maintenance therapy...

10/31/2024

Oncology

News

Safety of Encorafenib Plus Binimetinib and Pembrolizumab for Advanced BRAF V600-Mutant Melanoma

10/31/2024

A safety lead-in for the STARBOARD trial found that both doses of encorafenib under evaluation, in combination with binimetinib and pembrolizumab, demonstrated safety that was comparable to the known profile for each agent.

A safety lead-in for the...

10/31/2024

Oncology

News

Novel Next-Generation Sequencing Assay Proves Accurate in Detecting Mutations Among Patients Advanced HR-Positive, HER2-Negative Breast Cancer

10/31/2024

A multi-gene target panel NGS assay was found to be feasible and accurate when detecting mutations in patients with advanced HR-positive, HER2-negative breast cancer.

A multi-gene target panel NGS...

10/31/2024

Oncology

News

Fedratinib Demonstrates Promising Efficacy for Second-Line Treatment of Myelofibrosis

10/31/2024

According to a phase 3 trial, patients with myelofibrosis previously treated with ruxolitinib demonstrated superior spleen volume reduction and symptom response when treated with fedratinib compared with best available therapy.

According to a phase 3 trial,...

10/31/2024

Oncology